Is The Spring For Pharma Stocks Here? WuXi AppTec Rises Over 9% As Institutions Back An Industry Inflection
On March 24, Hong Kong’s pharmaceutical sector staged a pronounced rebound. At the time of reporting, WuXi AppTec (02359.HK) advanced 9.54%, Asymchem (06821.HK) rose 3.32%, WuXi Biologics (02269.HK) increased 3.02%, and Pharmaron (03759.HK) gained 2.61%.
Market participants attributed the rally to growing institutional confidence in the sector’s outlook. BOCOM International observed that, against a backdrop of recovering demand and a reshaped competitive landscape, the pharmaceutical industry is entering a phase characterized by rapid scale expansion and intensified selection among competitors. The firm highlighted that the internationalization of innovative drugs is driving industry enlargement and structural upgrading, consolidation among leading companies is accelerating, and AI‑driven drug discovery is expected to reach a development inflection in 2026.
Guosen Securities emphasized that domestic innovative drug clinical programs are progressing smoothly, with several strong clinical datasets recently presented at academic conferences. The broker recommended focusing on major second‑quarter events such as ASCO. Since the first quarter of 2026, multiple international collaboration agreements based on technology platforms have been signed, which Guosen interprets as validation of Chinese innovation’s efficiency and cost advantages by multinational pharmaceutical companies. The firm regards the CXO segment as the strongest current investment theme in healthcare, supported by both near‑term earnings realization and long‑term global competitiveness.
Ping An Securities noted that the AACR conference in San Diego, scheduled for April 17–22, 2026, will serve as a key barometer for oncology research, where numerous domestic and international companies will disclose pivotal clinical data. Among the items highlighted are Merck’s planned first disclosure of clinical results for MK‑2010 (a PD‑1/VEGF bispecific antibody licensed from Lepu Medicine) with an upfront payment of USD 588 million, and updates across RAS‑targeted pipelines from several developers.
WuXi AppTec led the market following its 2025 financial disclosure: revenue reached RMB 45.456 billion, up 15.84% year‑on‑year, while net profit attributable to shareholders rose 102.65% to RMB 19.151 billion. Excluding non‑recurring items, attributable net profit still recorded a 32.56% increase. The company proposed a cash dividend of approximately RMB 4.712 billion. For 2026, WuXi AppTec projected total revenue between RMB 51.3 billion and RMB 53.0 billion, with continuing operations expected to grow 18%–22%; capital expenditure is planned at RMB 6.5–7.5 billion, adjusted free cash flow is forecast at RMB 10.5–11.5 billion, and total cash dividends are targeted to rise to RMB 5.71 billion.
The recent expansion of Stock Connect eligibility also favored biopharma and healthcare names. Of 42 newly added Hong Kong listings, 13 companies—over 30%—belong to the biopharma and medical‑healthcare track, covering cell therapy, AI‑driven drug discovery, innovative small molecules, and antibody therapeutics. Many of these entrants are pre‑revenue biotech firms listed under Chapter 18A of the Hong Kong Exchange. Representative companies cited include CARsgen Therapeutics‑B, Insilico Medicine, PegBio‑B, Xianzhu Biotech‑B, and GeneFrontier‑B, which maintain pipelines across solid tumors, metabolic diseases, oncology, and autoimmune indications.
Analysts interpret the Stock Connect expansion as a market response to the state’s positioning of biopharma as a strategic emerging industry. With continued southbound capital inflows, the inclusion provides valuable liquidity to pre‑profit biotech companies that remain in high‑investment phases, and signals a new stage of Mainland‑Hong Kong biotech capital market integration that balances value discovery with industrial empowerment.
